Feeder cell products are needed to enhance growth of cells that are being cultured. The current process produces feeder cells by selecting a source for blood material containing mononuclear cells (MNCs) and other blood components, combining blood material from a plurality of donors, isolating the MNCs from the other blood components so as to form isolated heterogenous MNCs. Afterwards, the isolated heterogeneous MNCs is irradiated to produce the feeder cells.

The present invention relates to a cord blood plasma-derived exosome or a mimetic thereof and a pharmaceutical use thereof. More particularly, the present invention provides the use of a human cord blood plasma-derived exosome or an exosome mimetic that mimics the proteomic profile of the cord blood plasma-derived exosome for the improvement, prevention or treatment of various autoimmune diseases or wound healing.

Disclosed are novel cellular populations generated by explosion of monocytic cells to conditioned media of regenerative cells. In one embodiment said regenerative cells are umbilical cord endothelial cells and said cells are pre-activated to possess enhance ability to reprogram said monocytic lineage cells. In one embodiment monocyte lineage cells are collected from leukopaks by plastic adherence and subsequently cultured in a manner to generate cells similar to M2 cells. In one embodiment said monocytic cells are cultured in a manner to generate myeloid derived suppressor cells. In one embodiment cells are generated to reducing inflammatory conditions. In another embodiment cells are generated for treatment of degenerative conditions. In another embodiment cells are generated for treatment of fibrosis.

A cryovial device is disclosed including a vial configured to hold a liquid sample and an inlet/outlet tube coupled to the vial. The inlet/outlet tube is constructed of a weldable polymer and has a filled configuration, a closed configuration, and a drained configuration.

Present invention is related to a tumor microenvironment on chip or a biochip for cell therapy having a carrier, a first cell or tissue culture area and a second cell or tissue area imbedded within the carrier. The present invention provides a biochip successfully cooperating micro fluidic technology and cell culture achieving the goal for detecting or testing the function of cell therapy for cancer or tumor.

Certain exemplary embodiments are directed to a biologically active composition of matter (and uses thereof) configured for targeted delivery of biotin to mitochondria, the composition comprising a first D-biotin conjugated to a water-soluble, cell-permeable, peptide sequence, wherein the peptide sequence is selected from a polypeptide group with an alternating aromatic-cationic motif.

The present application provides peripheral blood mononuclear cells comprising an antigen, methods of manufacturing such PBMCs, and methods of using such PBMCs, such as for modulating an immune response in an individual. In some embodiments, the PBMCs are conditioned by incubating the PBMC in the presence of an adjuvant.

Aspects of the invention relate to cell culture vessels and method for using the vessels to agitate and maintain cells in suspension. In some embodiments, the vessel has a body configured to hold a volume of liquid containing cells to be cultured, the vessel body having a deformable portion arranged to induce movement of the liquid sufficient to maintain the cells in suspension. In some embodiments, the deformable portion is in at least one of a base and sidewall of the vessel body. In some embodiments, the deformable portion is deformed according to a deformable pattern. In some embodiments, the deformable portion is deformed via a deformation plate having one or more movable members that contact the deformable portion.

Methods for generating/expanding populations of immune cells comprising immune cells specific for an Epstein Barr Virus (EBV) lytic antigen are disclosed, the methods comprising stimulating immune cells specific for an EBV lytic antigen by contacting peripheral blood mononuclear cells (PBMCs) with: (i) one or more peptides corresponding to all or part of one or more EBV lytic antigens; or (ii) antigen presenting cells (APCs) presenting one or more peptides corresponding to all or part of one or more EBV lytic antigens. Also disclosed are populations of immune cells comprising immune cells specific for an EBV lytic antigen expanded according to such methods, and uses thereof.

The present invention provides isolated immune cells, immune cell populations and compositions, as well as markers, marker signatures and molecular targets characterising the immune cells. The cell products, substances, compositions, markers, marker signatures, molecular targets, kits of parts and methods of the present invention provide for new ways to characterise, evaluate and modulate the immune system and immune responses.